Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Vorapaxar in the Human Endotoxemia Model A Randomized, Double‐Blind, Crossover Study
Brief Summary: Vorapaxar is a recently approved protease activated receptor - 1 (PAR-1) inhibitor. Platelet inhibition may also exert positive results on coagulation activation and may beneficially influence the inflammatory response. Since vorapaxar is the first available substance of a new class of platelet inhibitors its effects on the human coagulation system and the inflammatory response will be assessed in the well-established human endotoxemia model.